Summary of Significant Accounting Policies (Details Narrative) (USD $)	3 Months Ended	12 Months Ended						1 Months Ended	12 Months Ended				1 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Minimum	Dec. 31, 2013 Maximum	Dec. 31, 2012 Other assets	Dec. 31, 2013 Tianjin Zhongke Blue Whale Information Technologies Co., Ltd. ('Blue Whale')	Dec. 31, 2013 Series A redeemable convertible preferred stock	Dec. 31, 2013 Stock option and restricted stock award	Dec. 31, 2012 Stock option and restricted stock award	Dec. 31, 2011 Stock option and restricted stock award	Dec. 31, 2013 Interest and other income (loss), net Tianjin Zhongke Blue Whale Information Technologies Co., Ltd. ('Blue Whale')	Dec. 31, 2013 Government securities and corporate debt securities	Dec. 31, 2012 Government securities and corporate debt securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash equivalents, fair value	$ 8,500,000	$ 8,500,000	$ 4,300,000
Restricted cash	800,000	800,000	800,000
Marketable securities, fair value	8,073,108	8,073,108	10,530,942											8,100,000	10,500,000
Amortization expense		122,951	118,789	323,540
Identifiable intangible assets, amortization expense, 2014	97,933	97,933
Identifiable intangible assets, amortization expense, 2015	58,797	58,797
Identifiable intangible assets, amortization expense, 2016	22,866	22,866
Estimated useful lives of the assets					3 years	7 years
Capitalized computer software amortization		339,589	301,263	140,326
Expected future amortization expense for software development costs, 2013	487,284	487,284
Expected future amortization expense for software development costs, 2014	487,284	487,284
Expected future amortization expense for software development costs, 2015	409,595	409,595
Expected future amortization expense for software development costs, 2016	228,481	228,481
Expected future amortization expense for software development costs, 2017	183,431	183,431
Foreign currency transaction gain (loss)		(1,073,000)	(653,000)	(78,000)
Common stock equivalents excluded from diluted net loss per share		16,931,548	11,532,032	14,982,611					8,781,516	8,150,032	11,532,032	14,982,611
Proceeds from sale of cost method investment		3,000,000	0	0				3,000,000
Gain on sale of joint venture	1,900,000	2,096,364	0	0									2,096,364
Cost method investments							900,000
Impairment charges recognized for other-than-temporary declines in cost method investments			$ 11,000	$ 42,000